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Abstract Melanin-concentrating hormone (MCH) is a
hypothalamic neuropeptide that acts on the MCH1 receptor.
MCH1R is expressed widely throughout the brain, partic-
ularly in regions thought to be involved in the regulation of
stress and emotional response. The role of MCH in anxiety
has been controversial, however. Central administration of
MCH has been reported to promote or reduce anxiety-like
behaviors. The anxiolytic activity of several MCH1R
antagonists has also been debated. To address this issue,
we have tested whether TPI 1361-17, a highly specific and
high affinity MCH1R antagonist, exerts anxiolytic effects in
two commonly used models of anxiety, the elevated plus
maze and the light–dark transition test. We show that this
MCH1R antagonist exerts potent anxiolytic effects in both
assays. Our study therefore supports previous studies
indicating that MCH1R antagonists may be useful in the
treatment of anxiety.
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Introduction
Melanin-concentrating hormone (MCH) was originally
isolated from salmon pituitaries as a hormone that induces
paling of the skin in teleost fish (Kawaguchi et al. 1983).
Subsequently, MCH was identified in the mammalian
hypothalamus as a cyclic nonadecapeptide (Vaughan et al.
1989). In mammals, MCH is expressed predominantly in
neurons of the lateral hypothalamus and the zona incerta
which project broadly throughout the brain to regions
involved in the regulation of feeding, energy homeostasis,
and mood related behaviors (Bittencourt et al. 1992). MCH
exerts its physiological and behavioral effects through two G
protein-coupled receptors, MCH1R (Bachner et al. 1999;
Chambers et al. 1999; Lembo et al. 1999; Saito et al. 1999;
Shimomura et al. 1999) and MCH2R (Sailer et al. 2001), but
only the MCH1 receptor is expressed in rodents (Tan et al.
2002). MCH1 receptors are widely distributed throughout the
CNS with particularly dense expression in the cortex,
hippocampus,amygdala,locuscoeruleus,andnucleusaccum-
bens shell (Saito et al. 2001).
The prominenceofMCH1Rinlimbicbrainregions hasled
tostudies onthe roleofthe MCHsysteminstressandanxiety.
The present conclusions of these studies, however, are
controversial. Central MCH injection has been reported to
be either anxiogenic (Smith et al. 2006) or anxiolytic
(Monzon and De Barioglio 1999;M o n z o ne ta l .2001)i n
the elevated plus maze. Microinjection of MCH into the
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DOI 10.1007/s12031-010-9425-ynucleus accumbens shell, an area of the brain where MCH
has been reported to potentiate dopamine signaling (Chung
et al. 2009), promotes depression-like behavior (Georgescu
et al. 2005). MCH1R knockout mice exhibit reduced anxiety
(Roy et al. 2006; Smith et al. 2006) and depression-like
behaviors (Georgescu et al. 2005) in several behavioral
paradigms. Finally, several groups have used MCH1R
antagonists to search for a link between the MCH system
andanxiety.In2002,theMCH1RantagonistSNAP-7941was
shown to produce anxiolytic effects in a social interaction test
and to reduce separation induced vocalization in guinea pig
pups (Borowsky et al. 2002). Additional MCH1R antago-
nists, SNAP 94847, ATC0065, ATC0175, and GW3430,
were found to also be anxiolytic in acute and chronic
anxiety behavioral paradigms (Shimazaki et al. 2006).
However, it has also been reported that MCH1R antago-
nists are ineffective in anxiety paradigms (Basso et al.
2006) and that several of the MCH1R antagonists reported
to be anxiolytic bind to targets other than MCH1R that
could contribute to the observed anxiolytic effects (Basso
et al. 2006), raising questions about whether inhibiting the
MCH system is sufficient to produce anxiolytic effects.
The present study examined the anxiolytic effects of a
MCH1 receptor antagonist, TPI 1361-17. This antagonist
exhibits high affinity (nM) and is specific for the MCH1
receptor (Nagasaki et al. 2009). In contrast to previously
reported MCH1R antagonists, TPI13161-17 does not cross
the blood–brain barrier and is thus administered intra-
cerebroventricularly (i.c.v.) which ensures that its central
effects are not affected by peripheral MCH-related
responses such as potential alterations in insulin levels
(Pissios et al. 2007). TPI1361-17 was therefore tested on
mice in two widely used behavioral assays for anxiety: the
elevated plus maze and the light–dark transition paradigms.
Materials and Methods
Animals
Male C57BL/6 mice (National Cancer Institute, Bethesda,
MD, USA; age, 7–8 weeks; weight, 23–25 g) were used in all
experiments. The animals were group-housed (four animals
per cage) under controlled conditions with a 12-h light–dark
cycle and withad libitum accesstofoodand water. All animal
experiments were approved by the University of California
Irvine Institutional Animal Care and Use Committee.
Drugs
TPI1361-17 was dissolved in phosphate-buffered saline
(pH 7.4) with 0.2% bovine serum albumin. Prior to i.c.v.
injection, mice were briefly anesthetized with isoflurane
and TPI1361-17 or vehicle was injected into the lateral
ventricle (i.c.v.) with 2 μL total volume using a Hamilton
syringe as described previously (Laursen and Belknap
1986; Xu et al. 2004). Mice were allowed to recover for
20 min prior to anxiety testing. Following completion of the
experiment, mice were euthanized and brains examined to
confirm correct injection site. Animals with an injection site
not in the lateral ventricle were excluded from the study.
Approximately 95% of injections were correctly placed.
Chlordiazepoxide (Sigma-Aldrich, St. Louis, MO, USA)
was dissolved on the morning of the experiment in saline.
Five milligrams per kilogram of chlordiazepoxide or saline
was injected i.p. in a volume of 4 ml/kg 20 min prior to
behavioral testing.
Elevated Plus Maze Paradigm
The elevated plus maze task was performed as described
previously with minor modifications (Koster et al. 1999;X u
et al. 2004). Briefly, the plus maze consisted of two open
(30×5 cm) and two wall-enclosed arms (30×5×15 cm)
connected by a central platform (5×5 cm) in a dimly lit
room. The apparatus was elevated 75 cm above the floor.
Mice were transferred in their home cages to the behavioral
testing room 1 h prior to the start of behavioral testing. The
test was started by placing a mouse in the central area of the
plus maze facing a closed arm which the animal usually
enters first. Exploratory behavior was monitored using an
automated video motility system (Video Mot II, TSE, Bad
Homburg, Germany). The numbers of entries into open
arms, time in open and closed arms, total number of zone
transitions, and latency until the first open-arm entry were
recorded and quantified. Entries were defined as the body
center of an animal entering a new zone.
Light–Dark Transition Paradigm
The light–dark transition test was performed as described
previously (Koster et al. 1999; Xu et al. 2004). The light–
dark box was divided into a lit compartment (30×20×
25 cm) and a dark compartment (15×20×25 cm) connected
by a 4-cm tunnel in a dimly lit room. Mice were initially
placed in the dark compartment. The number of entries into
the light compartment, time in light compartment, and
latency to enter light compartment during the 5-min test
were recorded using the same program as was used for
elevated plus maze experiments. Entries were defined as the
body center of an animal entering a different compartment.
Statistics
All statistical analysis was performed using Graphpad
Prism 5.0. Nonparametric variables such as the number of
J Mol Neurosci (2011) 43:132–137 133entries into each arm were analyzed by Pearson’s chi-square
test. All other parameters were analyzed by Student’s t test
or one-way analysis of variance with Bonferroni post-test.
In all experiments,
* p<0.05,
**p<0.01,
***p<0.001, and
#p<0.05 vs 0.5 nmol TPI-1361-17 group.
Results
Light–Dark Transition Test
The light–dark transition test was validated with mice
injected with 5 mg/kg chlordiazepoxide or saline. Mice
administered chlordiazepoxide spent significantly more
time in the light compartment (74.12 vs 41.78, p<0.05,
Table 1), exhibited more entries into the light compartment
(9.43 vs, 6.17 p<0.05, Table 1), and had a shorter latency
to first entry into the light compartment (11.23 vs 48.76, p<
0.05, Table 1) than vehicle injected control mice, indicating
an anxiolytic effect.
A separate group of mice was injected i.c.v. with either
0.5 or 1 nmol of TPI 1361-17 or vehicle and tested in the
light–dark transition test. Mice injected with 1 nmol TPI
1361-17 spent significantly more time in the light compart-
ment (66.12 vs 32.02, F2,27=9.73, p<0.01, Fig. 1a), entered
the light compartment more times (8.3 vs 5.6, F2,27=3.55,
p<0.05, Fig. 1b) and had a shorter latency to first entry into
the light compartment (16.46 vs 39.25, F2,27=3.66, p<0.05,
Fig. 1c) than vehicle-injected animals, and also spent
significantly more time in the light compartment than mice
injected with 0.5 nmol TPI 1361-17 (66.12 vs 45.19, F2,27=
9.74, p<0.05, Fig. 1a). Mice injected with 0.5 nmol TPI
1361-17 exhibited trends toward reduced anxiety like
behaviors (Fig. 1).
Elevated Plus Maze
To validate the assay, mice were injected with 5 mg/kg i.p.
chlordiazepoxide or saline and tested on the elevated plus
maze. Mice administered chlordiazepoxide showed a
significant increase in time spent on the open arms (42.78
vs 20.44, p<0.05, Table 1), and the number of entries into
open arms (9.00 vs 4.78, p<0.05, Table 1), and exhibited a
strong trend towards a shorter latency to first entry onto an
open arm (Table 1).
A separate group of mice was injected i.c.v. with 1 nmol
TPI 1361-17 or vehicle and tested on the elevated plus
maze. Mice injected with TPI 1361-17 spent more time on
the open arms of the plus maze (38.9 vs 6.99, p<0.01,
Fig. 2a), and entered the open arms more frequently (7.6 vs
5.0, p<0.05, Fig. 2b) than vehicle-injected animals. TPI
1361-17 injected mice trended toward a shorter latency to
first open arm entry (Fig. 2c).
Discussion
The elevated plus maze and light–dark transition tests
are commonly used mouse models of anxiety-like
behavior. Compounds with anxiolytic effects cause mice
to spend more time in and enter more frequently the
open arms of the elevated plus maze or the lit
compartment of the light–dark box (Lister 1987; Bourin
and Hascoet 2003). In the present study, we first used the
benzodiazepine chlordiazepoxide to validate two assays,
the light–dark transition test and the elevated plus maze
paradigms, and then demonstrated that the selective
MCH1R antagonist TPI 1361-17 exerts potent anxiolytic
effects in these models.
There was no observed effect on the total number of
transitions between zones in the elevated plus maze (15.40±
2.056 vs 17.90±1.224), indicating that central administra-
tion of TPI 1361-17 is not sedative, which is consistent with
a previous report that TPI 1361-17 does not alter locomotor
activity (Nagasaki et al. 2009). The fact that TPI 1361-17-
injected mice spend more time in the non-protected zones
of both assays indicates that TPI 1361-17 exerts anxiolytic
effects. A dose-dependent relationship is present for
anxiolytic effects in the light–dark transition assay. Al-
though it is not possible to accurately compare the
magnitude of the anxiolytic effects of chlordiazepoxide
and TPI 1361-17 as presented in this study due to
Table 1 Validation of light–dark transition test and elevated plus maze
Light–dark transition test Elevated plus maze
Vehicle Chlordiazepoxide Vehicle Chlordiazepoxide
Time spent in open arms (s) 41.78±7.29 74.12±10.13* 20.44±3.44 42.78±7.67*
Entries into light compartment/open arms 6.167±0.87 9.43±0.72* 4.78±0.57 9.00±0.65***
Latency to first entry into light compartment/open arms 48.76±14.90 11.23±2.94* 37.38±7.27 20.21±5.25
The effects of 5 mg/kg i.p. chlordiazepoxide on time spent in the light compartment/open arms, number of entries into the light compartment/open
arms, and the latency to first entry into the light compartment/open arms in the light–dark transition test and elevated plus maze
134 J Mol Neurosci (2011) 43:132–137differences in experimental procedure, i.c.v. injection of
TPI 1361-17 causes a reduction of anxiety-like behavior
that appears similar to that observed with 5 mg/kg
chlordiazepoxide i.p. in both behavioral paradigms, indi-
cating that the inhibition of the MCH system has a potent
effect on anxiety-like behavior.
TPI 1361-17 is a highly specific MCH1R antagonist that
inhibits its receptor at nanomolar concentrations and does
not display activity or binding to any targets tested in an
array of G-protein protein coupled receptors and channels
(Nagasaki et al. 2009). TPI 1361-17 has been shown to be
effective in vivo, since it blocks MCH-induced food intake
(Nagasaki et al. 2009) and inhibits acute cocaine self-
administration (Chung et al. 2009). The high degree of
specificity indicates that the anxiolytic effects of TPI1361-
17 are entirely due to blockade of the MCH system and that
off-target effects are unlikely to contribute to the observed
effect. Central administration of TPI 1361-17 eliminates the
possibility of any peripheral effects of the compound
contributing to the anxiolytic effects. This evidence
supports MCH involvement in the regulation of anxiety
and stress response (Smith et al. 2006, 2009)a n di s
consistent with previous reports indicating that MCH1R
antagonists are anxiolytic and may be useful in treating
anxiety disorders.
The mechanisms underlying the anxiolytic activity of
MCH antagonists are unknown, but several lines of
evidence indicate that multiple factors may contribute to
this effect. MCH has been reported to modulate the
hypothalamic–pituitary adrenal axis (Smith et al. 2006,
2009), possibly by activating neurons in the paraventricular
nucleus and increasing ACTH and corticosterone release
(Herman et al. 1996; Smith et al. 2006), suggesting that
MCH may regulate anxiety and stress response at least
partially through this circuit. It has also been reported that
microinjection of MCH into the nucleus accumbens shell
induces depressive-like effects (Georgescu et al. 2005), and
it was recently discovered that MCH modulates dopamine
signaling in this region (Chung et al. 2009), suggesting that
the effects of MCH on depression-like behavior may
involve the dopamine system. Anxiety and depressive
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Figure 2 Elevated plus maze. The effect of i.c.v. injection of vehicle
or 1 nmol TPI 1361-17 on a time spent on the open arm, b number of
entries onto the open arm, and c Latency to first entry onto an open
arm (N=10 animals per group)
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Figure 1 Light–dark transition test. The effects of i.c.v. injection of
vehicle, 0.5 nmol TPI 1361-17, 1 nmol TPI 1361-17 on a time spent
in the light compartment, b number of entries into the light
compartment, and c and latency to first entry into light compartment
(N=9–10 animals per group)
J Mol Neurosci (2011) 43:132–137 135disorders are closely linked and express with high comor-
bidity (Dunlop and Davis 2008), suggesting that the
anxiolytic and antidepressant effects of MCH antagonists
could occur through similar mechanisms and that the role of
MCH in anxiety could thus also involve the mesolimbic
dopamine system. Although little is known about the role
of MCH in the amygdala, MCH projects to (Bittencourt et
al. 1992) and MCH1R is highly expressed in several nuclei
of the amygdala (Saito et al. 2001), in areas in which other
neuropeptide systems are known to regulate anxiety (Tasan
et al. 2010).
We have shown that acute central administration of the
specific MCH1R antagonist TPI 1361-17 exerts potent
anxiolytic effects in two of the most common and accepted
anxiety behavioral paradigms. The high specificity of TPI
1361-17 indicates that its anxiolytic effects are caused by
blockade of MCH1R alone. These results support previous
studies indicating that MCH1R is a viable target for the
development of novel anxiolytic drugs and suggests that the
reported anxiolytic effects of other MCH1R antagonists are
caused by blockade of the MCH system and are not due to
off target effects.
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